RxDoctor Payments Data

Shawn Allen

Neurology · St George, UTNPI 1083147441

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (45.8%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 40 manufacturers reported payments, led by Johnson & Johnson at 58.7% of the total. 2025 is the largest year on record at $29,794, more than ten times the $123 reported in 2022.

$35,573in general payments, 2019–2025

Across 333 payments — averaging $106.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$21K
  • Argenx US, Inc.$8K
  • Abbott$1K
  • AbbVie$1K
  • Boston Scientific$595
  • Biogen$567
  • plus $3K from 34 others

What the payments were for

  • Consulting fees$6,13817%
  • Speaking & faculty fees$16,28046%
  • Travel & lodging$6,10817%
  • Food & beverage$6,91419%
  • Education$1330%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$35,573 in reported general payments places this provider in the 85th percentile of 157 neurology providers in Utah.

See all neurology providers in Utah

Medicare billing

Part B allowed, 2024
$324,462
Medicare patients
783
Services billed
17,045

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OctagamImmun Globg(Igg)/Malt/Iga Ov5045$927,259
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5014$146,302
BotoxOnabotulinumtoxina32$40,418
QuliptaAtogepant23$24,204
Nurtec OdtRimegepant Sulfate20$23,242
Emgality PenGalcanezumab-Gnlm20$19,605
RexultiBrexpiprazole13$19,388
UbrelvyUbrogepant13$16,292
NeuproRotigotine14$12,438
Memantine Hcl160$4,623
Carbidopa-LevodopaCarbidopa/Levodopa161$3,899
Lacosamide46$2,808
Carbidopa-Levodopa ErCarbidopa/Levodopa49$2,561
Pyridostigmine Bromide34$1,883
Riluzole16$1,845

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerOctagam, Nurtec Odt$340$950,50065 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$20$146,30214 claims
AbbVieBotox, Qulipta, Ubrelvy$1,077$80,91468 claims
Otsuka America Pharmaceutical, Inc.Rexulti$17$19,38813 claims
UCB, Inc.Neupro$96$12,43814 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$16$1,88334 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 157 neurology providers in Utah.

Other neurology in St George

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →